×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARWR – arrowhead pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARWR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/17
07:07 pm
arwr
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma [Yahoo! Finance]
3/14
02:44 pm
arwr
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift [Yahoo! Finance]
Medium
Report
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift [Yahoo! Finance]
3/10
04:43 am
arwr
Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead [Yahoo! Finance]
3/4
11:08 pm
arwr
ClearBridge Small Cap Growth Portfolios Q4 2025 Commentary [Seeking Alpha]
Low
Report
ClearBridge Small Cap Growth Portfolios Q4 2025 Commentary [Seeking Alpha]
3/4
09:16 pm
arwr
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference [Yahoo! Finance]
3/1
07:02 pm
arwr
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns [Yahoo! Finance]
Low
Report
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns [Yahoo! Finance]
2/27
07:01 am
arwr
Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines [Yahoo! Finance]
Low
Report
Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines [Yahoo! Finance]
2/24
07:43 am
arwr
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/5/2026
04:05 pm
ARWR
arrowhead pharmaceuticals, inc.
MISS
Report
-0.2%
arrowhead pharmaceuticals, inc.
11/25/2025
04:00 pm
ARWR
arrowhead pharmaceuticals, inc.
MISS
Report
23.3%
arrowhead pharmaceuticals, inc.
8/7/2025
04:01 pm
ARWR
arrowhead pharmaceuticals, inc.
MISS
Report
2.2%
arrowhead pharmaceuticals, inc.
5/12/2025
04:01 pm
ARWR
arrowhead pharmaceuticals, inc.
BEAT
Report
9.4%
arrowhead pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/9
07:00 pm
arwr
Form 4 ARROWHEAD PHARMACEUTICAL For: Mar 05 Filed by: Hamilton James C
Low
Report
Form 4 ARROWHEAD PHARMACEUTICAL For: Mar 05 Filed by: Hamilton James C
3/5
04:50 pm
arwr
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: Hamilton James C
Medium
Report
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: Hamilton James C
2/5
04:07 pm
arwr
Form 10-Q ARROWHEAD PHARMACEUTICAL For: Dec 31
Low
Report
Form 10-Q ARROWHEAD PHARMACEUTICAL For: Dec 31
2/5
04:05 pm
arwr
Form 8-K ARROWHEAD PHARMACEUTICAL For: Feb 05
Low
Report
Form 8-K ARROWHEAD PHARMACEUTICAL For: Feb 05
1/27
06:02 am
arwr
Form ARS ARROWHEAD PHARMACEUTICAL For: Jan 26
Low
Report
Form ARS ARROWHEAD PHARMACEUTICAL For: Jan 26
1/27
06:00 am
arwr
Form DEFA14A ARROWHEAD PHARMACEUTICAL
Low
Report
Form DEFA14A ARROWHEAD PHARMACEUTICAL
1/27
06:00 am
arwr
Form DEF 14A ARROWHEAD PHARMACEUTICAL For: Jan 26
Low
Report
Form DEF 14A ARROWHEAD PHARMACEUTICAL For: Jan 26
1/21
12:32 pm
arwr
Form SCHEDULE 13G/A ARROWHEAD PHARMACEUTICAL Filed by: BlackRock, Inc.
Low
Report
Form SCHEDULE 13G/A ARROWHEAD PHARMACEUTICAL Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
Bragar Eagel & Squire is Investigating Certain Officers and Directors of comScore, Mammoth Energy, AMC Entertainment, and Arrowhead Pharmaceuticals and Encourages Investors to Contact the Firm
23.9%
11/25 Form 8-K ARROWHEAD PHARMACEUTICAL For: Nov 25 19.2%
12/2 Form 424B5 ARROWHEAD PHARMACEUTICAL 12.5%
3/19 Form 8-K ARROWHEAD PHARMACEUTICAL For: Mar 14 9.3%
11/25 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. 8.8%
8/5 Form 8-K ARROWHEAD PHARMACEUTICAL For: Aug 05 6.8%
4/20 Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Incredible 2370% Share Price Run Shows What Is Possible With Stocks [Yahoo! Finance News] 6.4%
11/7 Form 4 ARROWHEAD PHARMACEUTICAL For: Nov 05 Filed by: Myszkowski Kenneth Allen 6.3%
5/8 Q2/2019 3/31/2019 EPS 0.240 ZacksConsensus 0.220 ActVsEst 0.020 - Beat 6.1%
8/19 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at B. Riley from $32.00 to $46.00. They now have a "buy" rating on the stock. 5.4%
11/25 Form 8-K ARROWHEAD PHARMACEUTICAL For: Nov 25 19.2%
12/2 Form 424B5 ARROWHEAD PHARMACEUTICAL 12.5%
3/19 Form 8-K ARROWHEAD PHARMACEUTICAL For: Mar 14 9.3%
11/25 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. 8.8%
8/5 Form 8-K ARROWHEAD PHARMACEUTICAL For: Aug 05 6.8%
4/20 Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Incredible 2370% Share Price Run Shows What Is Possible With Stocks [Yahoo! Finance News] 6.4%
11/7 Form 4 ARROWHEAD PHARMACEUTICAL For: Nov 05 Filed by: Myszkowski Kenneth Allen 6.3%
5/8 Q2/2019 3/31/2019 EPS 0.240 ZacksConsensus 0.220 ActVsEst 0.020 - Beat 6.1%
8/19 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at B. Riley from $32.00 to $46.00. They now have a "buy" rating on the stock. 5.4%
TOP News Decliners
3/15
Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Salary Justified? [Yahoo! Finance News]
-16.8%
2/6 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at Cantor Fitzgerald from $50.00 to $55.00. They now have a "neutral" rating on the stock. -13.5%
12/2 3 Soaring Biotech Stocks to Watch in December [The Motley Fool] -13.3%
1/21 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is now covered by analysts at Svb Leerink Llc. They set an "underperform" rating and a $32.00 price target on the stock. -10.5%
3/9 Why Arrowhead Pharmaceuticals Shares Dropped 15% in February [The Motley Fool] -7.5%
4/29 Form 4 ARROWHEAD PHARMACEUTICAL For: Apr 27 Filed by: GIVEN BRUCE D -7.4%
10/23 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was given a new $46.00 price target on by analysts at B. Riley. They now have a "buy" rating on the stock. -7.0%
8/22 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -6.9%
6/27 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating. -6.8%
12/20 Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease -6.6%
2/6 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at Cantor Fitzgerald from $50.00 to $55.00. They now have a "neutral" rating on the stock. -13.5%
12/2 3 Soaring Biotech Stocks to Watch in December [The Motley Fool] -13.3%
1/21 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is now covered by analysts at Svb Leerink Llc. They set an "underperform" rating and a $32.00 price target on the stock. -10.5%
3/9 Why Arrowhead Pharmaceuticals Shares Dropped 15% in February [The Motley Fool] -7.5%
4/29 Form 4 ARROWHEAD PHARMACEUTICAL For: Apr 27 Filed by: GIVEN BRUCE D -7.4%
10/23 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was given a new $46.00 price target on by analysts at B. Riley. They now have a "buy" rating on the stock. -7.0%
8/22 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -6.9%
6/27 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating. -6.8%
12/20 Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease -6.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: